HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC Continues Product Lineup Changes Under Harbin Pharmaceutical Ownership

Executive Summary

After selling to Harbin Pharmaceutical Holding Group Co. LLC in 2021, GNC continues to expand its product line by adding Bucked Up LFG pre-workout supplement to its websites and stores nationwide.

You may also be interested in...



GNC Continues Private Evolution With TikTok Influencers Evolving To Fitness Brand Marketers

Product distribution for Sway Fitness expands to national chain as reach of social media influencers, particularly boys and girls, men and women and groups on TikTok, passes suggesting or recommending to selling products and services.

GNC’s Sale Attracts No Competitors For Harbin’s Bid; Chapter 11 Bankruptcy Auction Cancelled

Deadline passed for “other qualified bidders to submit higher or otherwise better offers to purchase” full ownership of GNC. Approving sale to Harbin Pharmaceuticals, already its largest shareholder, depends partly on approval by US bankruptcy court, where a hearing is set for 17 September.

GNC Missed Opportunities To Drive Growth On Changing Trends

Jefferies analysts point out more sales of supplements, particularly sports nutrition products, already were moving online before COVID-19 prompted quarantine orders and spike e-commerce sales. GNC could have capitalized but didn’t have capital available to make its online sales platform and operations large enough to support potential growth.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel